Antifungal activity of a human antiglucuronoxylomannan antibody

Clinical and Diagnostic Laboratory Immunology

Volumn 5, Issue 1, 1998, Pages 58-64

  Zhong, Zhaojing ^a   Pirofski, Liise Anne ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIFUNGAL ACTIVITY; ARTICLE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HUMAN; HUMAN CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL;

EID: 0031907654     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.5.1.58-64.1998     Document Type: Article

References (54)

1. Allen, L.-A., and A. Aderem. 1996. Molecular definition of distinct cytoskeletal structures involved in complement-and Fe receptor-mediated phagocytosis by macrophages. J. Exp. Med. 184:627-637.
2. Bennett, J. E., K. J. Kwon-Chung, and D. H. Howard. 1977. Epidemiologic differences among serotypes of Cryptococeus neoformans. Am. J. Epidemiol. 105:582-586.
3. Bjerknes, R. 1984. Flow cytoimetric assay for combined measurement of phagocytosis and intracellular killing of Candida albicans. J. Immunol. Methods 72:229-241.
4. Bjerknes, R., and C. F. Bassoe. 1983. Human leukocyte phagocytosis of zymosan particles measured by flow cytometry. Acta Pathol. Microbiol. Immunol. Scand. Sect. C 91:341-348.
5. Bjerknes, R., C. F. Bassoe, H. Sjursen, O. D. Laerum, and C. O. Solberg. 1989. Flow cytometry for the study of phagocyte functions. Rev. Infect. Dis. 11:16-24.
6. Bjornson, A. B., and P. A. Detmers. 1995. The pentameric structure of IgM is necessary to enhance opsonization of Bacteroides thetaiotaomicron and Bacteroides fragilis via the alternative complement pathway. Microb. Pathog. 29:117-128.
7. Brown, E. J., S. W. Hosea, C. H. Hammer, G. Burch, and M. M. Frank. 1982. A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J. Clin. Invest. 69: 85-98.
8. Brown, E. J., K. A. Joiner, R. M. Cole, and M. Berger. 1983. Localization of complement component 3 on Streptococcus pneumoniae: anticapsular antibody causes complement deposition on the pneumococcal capsule. Infect. Immun. 39:403-409.
9. Casadevall, A., M. DeShaw, M. Fan, F. Dromer, T. R. Kozel, and L. Pirofski. 1994. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:3864-3872.
10. Casadevall, A., J. Mukherjee, S. J. Devi, R. Schneerson, J. B. Robbins, and M. D. Scharff. 1992. Antibodies elicited by a Cryptococcus neonformanstetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 165:1086-1093.
11. Casadevall, A., J. Mukherjee, and M. D. Scharff. 1992. Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J. Immunol. Methods 154: 27-35.
12. Casadevall, A., and M. D. Scharff. 1994. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob. Agents Chemother. 38:1695-1702.
13. Casadevall, A., and M. D. Scharff. 1995. Return to the past: the case for antibody-based therapies in infectious diseases. Clin. Infect. Dis. 21:150-161.
14. Chaka, W., J. Scharringa, A. F. M. Verheul, J. Verhoef, A. G. Van Strijp. and I. M. Hoepelman. 1995. Quantitative analysis of phagocytosis and killing of Cryptococcus neoformans by human peripheral blood mononuclear cells by flow cytometry. Clin. Diagn. Lab. Immunol. 2:753-759.
15. Currie, B. P., and A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin. Infect. Dis. 19:1029-1033.
16. Davies, S. F., D. P. Clifford, J. R. Hoidal, and J. E. Repine. 1982. Opsonic requirements for the uptake of Cryptococcus neoformans by human polymorphonuclear leukocytes and monocytes. J. Infect. Dis. 145:870-874.
17. DeShaw, M., and L. Pirofski. 1995. Antibodies to Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan are ubiquitous in the serum of HlV and HIV individuals. Clin. Exp. Immunol. 99:425-432.
18. DeVelasco, E. A., H. A. Dekker, P. Antal, K. P. Jalink, J. A. van Strijp, A. F. Verbeul, J. Verhoef, and H. Snippe. 1994. Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumocuccal polysaccharide conjugate vaccines. Vaccine 12:1419-1422.
19. Devi, S. J. 1996. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14:841-844.
20. Devi, S. J. N., R. Schneerson, W. Egan, T. J. Ulrich, D. Bryla, J. B. Robbins, and J. E. Bennett. 1991. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59:3700-3707.
21. Diamond, R. D. 1974. Antibody-dependent killing of Cryptococcus neoformans by human peripheral blood mononuclear cells. Nature 247:148-150.
22. Diamond, R. D., J. E. May, M. A. Kane, M. M. Frank, and J. E. Bennett. 1974. The role of the classical and alternative complement pathways in host defenses against Cryptococcus neoformans infection. J. Immunol. 112:2260-22710.
23. Diamond, R. D., R. K. Root, and J. E. Bennett. 1972. Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro. J. Infect. Dis. 125:367-376.
24. Diamond, R. E. 1995. Cryptococcus neuformans, p. 2331-2339. In G. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York. N.Y.
25. Drevets, D. A., and P. A. Campbell. 1991. Macrophage phagocytosis: use of fluorescence microscopy to distinguish between extracellular and intracellular bacteria. J. Immunol. Methods 142:31-38.
26. Dromer, F., P. Aucouturier, J. Clauvel, G. Saimot, and P. Yeni. 1988. Cryptococcus neoformans antibody levels in patients with AIDS. Scand. J. Infect. Dis. 20:283-285.
27. Dromer, F., S. Mathoulin, B. Dupont, L. Letenneur, and O. Ronin. 1996. Individual and environmental factors associated with infection due to Cryptococus neoformans serotype D. French Cryptococcosis Study Group. Clin. Infect. Dis. 23:91-96.
28. Fleuridor, R., R. Jefferis, R. Mageed, and L. Pirofski. 1997. Characterization of isotypes and idiotypes in sera from recipients of the GXM-TT vaccine, Abstracts of the 97th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.
29. Hostetter, M. K. 1986. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J. Infect. Dis. 153:682-693.
30. Houpt, D. C., T. Pfrommer, B. J. Young, T. A. Larson, and T. R. Kozel. 1994. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human scrum that are reactive with Cryptococcus neuformans glucuronoxylomannan. Infect. Immun. 62:2857-2864.
31. Kaplan, G. 1977. Differences in the mode of phagocytosis with Fc and C3 receptors in macrophages. Scand. J. Immunol. 6:797-806.
32. Konishi, E., and M. Nakao. 1992. Naturally occurring immunoglobulin M antibodies: enhancement of phagocytic and microbicidal activities of human neutrophils against Toxoplasma gondii. Parasitology 104:427-432.
33. Kozel, T. R. 1993. Opsonization and phagocytosis of Cryptococcus neoformans. Arch. Med. Res. 24:211-218.
34. Kozel, T. R., B. A. Highison, and C. J. Stratton. 1984. Localization on encapsulated Cryptococcus neoformans of serum components opsonic for phagocytosis by macrophages and neutrophils. Infect. Immun. 43:574-579.
35. Kozel, T. R., G. S. Pfrommer, and D. Redelmun. 1987. Activated neutrophils exhibit enhanced phagocytosis of Cryptococcus neoformans opsonized with normal human serum. Clin. Exp. Immunol. 70:238-246.
36. Kozel, T. R., M. A. Wilson, and J. W. Murphy. 1991. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect. Immun. 59:3101-3110.
37. Kuhlman, M., K. Joiner, and A. B. Ezekowitz. 1989. The human mannosebinding protein functions as an opsonin. J. Exp. Med. 169:1733-1745.
38. Laxalt, K. A., and T. R. Kozel. 1979. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and nonencapsulated Cryptococcus neoformans. Infect. Immun. 26:435-440.
39. Mandrell, R. E., R. H. Azmi, and D. M. Granoff. 1995. Complement-mediated bactericidal activity of human antibodies to poly alpha 2-8 N-acetyl-neuraminic acid, the capsular polysaccharide of Neisseria meningitidis sero-group B. J. Infect. Dis. 172:1279-1289.
40. Miller, M. F., and T. G. Mitchell. 1991. Killing of Cryptococcus neoformans strains by human neutrophils and monocytes. Infect. Immun. 59:24-28.
41. Mukherjee, S., S. C. Lee, and A. Casadevall. 1995. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63:573-579.
42. Nabavi, N., and J. W. Murphy. 1986. Antibody-dependent natural killer cell-mediated growth inhibition of Cryptococcus neoformans. Infect. Immun. 51:556-562.
43. Peake, P. W., J. A. Charlesworth, and B. A. Pussell. 1991. Activation of rabbit C3: studies of the generation of cleavage products in vitro and of their metabolism in vivo. Complement Inflammation 8:261-270.
44. Pirofski, L., and A. Casadevall. 1996. Cryptococcus neuformans: paradigm for the role of antibody in immunity. Zentralbl. Bakteriol. 284:475-495.
45. Pirofski, L., R. Lui, M. DeShaw, A. B. Kressel, and Z. Zhong. 1995. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect. Immun. 63:3005-3014.
46. Plasman, N., and B. Vray. 1994. Quantification of bacterial phagocytosis by flow cytometry and spectrofluorimetry. J. Immunol. Methods 174:195-202.
47. 2 fragments administered intranasally. J. Infect. Dis. 173:1123-1128.
48. Robbins, J. B., R. Schneerson, M. P. Glode, W. Vann, M. Schiffer, T. Y. Liu, J. C. Parke, and C. Huntley. 1975. Cross-reactive antigens and immunity to diseases caused by encapsulated bacteria. J. Allergy Clin. Immunol. 56:1387-1398.
49. Sasano, M., D. R. Burton, and G. J. Silverman. 1993. Molecular selection of human antibodies with an unconventional bacterial B cell antigen. J. Immunol. 151:5822-5839.
50. Schlesinger, L. S., and M. A. Horwitz. 1994. A role for natural antibody in the pathogenesis of leprosy: antibody in nonimmune serum mediates C3 fixation to the Mycobacterium leprae surface and hence phagocytosis by human mononuclear phagocytes. Infect. Immun. 62:280-289.
51. Tacker, J. R., F. Farhi, and G. S. Bulmer. 1972. Intraccllular fate of Cryptococcus neoformans. Infect. Immun. 6:162-167.
52. Takayanagi, T., H. Kawaguchi, Y. Yabu, M. Itoh, and K. Yano. 1992. Inhibition of IgM antibody-mediated aggregation of Toxoplasma gambiense in the presence of complement. Experientia 48:1002-1006.
53. Zhang, H., Z. Zhong, and L. Pirofski. 1997. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody. Infect. Immun. 65:1158-1164.
54. Zhong, Z., and L. Pirofski. 1996. Opsonization of Cryptococcus neoformans by human antiglucuronoxylomannan antibodies. Infect. Immun. 64:3446-3450.